Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 6Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Neuroendocrine Tumors 12Carcinoma, Neuroendocrine 8Carcinoma, Non-Small-Cell Lung 4Adrenocortical Carcinoma 4Thyroid Neoplasms 3Lung Neoplasms 3Carcinoid Tumor 3Vulvar Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Small Cell Lung Carcinoma 2Sarcoma 2Pheochromocytoma 2Penile Neoplasms 2Parathyroid Neoplasms 2Paraganglioma 2Ovarian Neoplasms 2Osteosarcoma 2Neurofibrosarcoma 2Mesothelioma 2Melanoma 2Hemangiosarcoma 2Gastro-enteropancreatic neuroendocrine tumor 2Gallbladder Neoplasms 2Cholangiocarcinoma 2Carcinosarcoma 2Carcinoma, Renal Cell 2Carcinoma, Adenoid Cystic 2Adrenal Gland Neoplasms 2

Interventions

Radiotherapy 2Ifosfamide 2Filgrastim 2Doxorubicin 2fludarabine 1aldesleukin 1Ritonavir 1Nivolumab 1Ipilimumab 1Indinavir 1Cyclophosphamide 1Chemotherapy, Adjuvant 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytoma, Malignant Fibrous × Nivolumab × Endocrine × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡